Market Mover: CTI (CTIC) Gains at Midday August 5

Equities Staff  |

Shares of CTI BioPharma Corp (NASDAQ: CTIC) rose 10.43% Friday.

As of 11:52:12 est, CTI is currently sitting at $7.59 and has risen $0.725 per share.

CTI has moved 16.64% over the last 30 days and has a YTD change of 193.95% based on the previous close.

The company is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on CTI visit the company profile.

About CTI BioPharma Corp

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington.

To get more information on CTI BioPharma Corp and to follow the company's latest updates, you can visit the company's profile page here: CTI BioPharma Corp's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content